Abstract

The RTS,S malaria vaccine may soon be licensed. Models of impact of such vaccines have mainly considered deployment via the World Health Organization's Expanded Programme on Immunization (EPI) in areas of stable endemic transmission of Plasmodium falciparum, and have been calibrated for such settings. Their applicability to low transmission settings is unclear. Evaluations of the efficiency of different deployment strategies in diverse settings should consider uncertainties in model structure. An ensemble of 14 individual-based stochastic simulation models of P. falciparum dynamics, with differing assumptions about immune decay, transmission heterogeneity, and treatment access, was constructed. After fitting to an extensive library of field data, each model was used to predict the likely health benefits of RTS,S deployment, via EPI (with or without catch-up vaccinations), supplementary vaccination of school-age children, or mass vaccination every 5 y. Settings with seasonally varying transmission, with overall pre-intervention entomological inoculation rates (EIRs) of two, 11, and 20 infectious bites per person per annum, were considered. Predicted benefits of EPI vaccination programs over the simulated 14-y time horizon were dependent on duration of protection. Nevertheless, EPI strategies (with an initial catch-up phase) averted the most deaths per dose at the higher EIRs, although model uncertainty increased with EIR. At two infectious bites per person per annum, mass vaccination strategies substantially reduced transmission, leading to much greater health effects per dose, even at modest coverage. In higher transmission settings, EPI strategies will be most efficient, but vaccination additional to the EPI in targeted low transmission settings, even at modest coverage, might be more efficient than national-level vaccination of infants. The feasibility and economics of mass vaccination, and the circumstances under which vaccination will avert epidemics, remain unclear. The approach of using an ensemble of models provides more secure conclusions than a single-model approach, and suggests greater confidence in predictions of health effects for lower transmission settings than for higher ones.

Highlights

  • Malaria vaccines have long been awaited by public health planners [1]

  • To contribute to addressing these questions, we previously developed a stochastic simulation model of malaria epidemiology and vaccination [5], and used this to make predictions of the likely impact of potential malaria vaccines with a wide range of characteristics, using a limited set of deployment options in African health systems at various transmission levels [6]

  • This analysis was limited by depending on the assumptions of a single model for malaria transmission dynamics, pathogenesis, and immunity (Table 1)

Read more

Summary

Introduction

Malaria vaccines have long been awaited by public health planners [1]. Promising results of recent phase II trials [2,3] and a current large-scale phase III trial of the RTS,S vaccine increase the urgency of understanding the potential benefits of a licensed malaria vaccine [4]. To contribute to addressing these questions, we previously developed a stochastic simulation model of malaria epidemiology and vaccination [5], and used this to make predictions of the likely impact of potential malaria vaccines with a wide range of characteristics, using a limited set of deployment options in African health systems at various transmission levels [6]. Models of impact of such vaccines have mainly considered deployment via the World Health Organization’s Expanded Programme on Immunization (EPI) in areas of stable endemic transmission of Plasmodium falciparum, and have been calibrated for such settings. At present there is no licensed malaria vaccine, but one promising vaccine—RTS,S—is currently undergoing phase III clinical trials (the last stage of testing before licensing) in infants and children in seven African countries

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call